| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
16,677 |
15,996 |
$3.34M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,627 |
7,270 |
$2.21M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,245 |
2,126 |
$329K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
367 |
347 |
$182K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,792 |
1,573 |
$100K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
519 |
493 |
$57K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,041 |
940 |
$55K |
| 80053 |
Comprehensive metabolic panel |
6,549 |
6,154 |
$32K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,063 |
1,774 |
$28K |
| 71046 |
Radiologic examination, chest; 2 views |
337 |
330 |
$20K |
| 71045 |
Radiologic examination, chest; single view |
257 |
244 |
$16K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,953 |
10,250 |
$16K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
285 |
277 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
381 |
372 |
$11K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
34 |
34 |
$9K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
115 |
51 |
$5K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
28 |
28 |
$5K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
68 |
24 |
$4K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
35 |
26 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
8,521 |
7,806 |
$3K |
| 70450 |
Computed tomography, head or brain; without contrast material |
13 |
13 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
43 |
40 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,165 |
1,088 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
111 |
109 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
13 |
13 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
105 |
86 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,864 |
2,530 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
15 |
14 |
$1K |
| 81001 |
|
915 |
853 |
$1K |
| 83690 |
|
1,053 |
993 |
$1K |
| 86140 |
|
609 |
574 |
$954.51 |
| 97161 |
|
15 |
15 |
$813.16 |
| 84484 |
|
386 |
303 |
$598.32 |
| J2704 |
Injection, propofol, 10 mg |
405 |
235 |
$589.64 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
661 |
349 |
$367.92 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
523 |
495 |
$217.42 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
249 |
242 |
$215.01 |
| 80306 |
|
81 |
78 |
$201.24 |
| 84703 |
|
98 |
91 |
$191.75 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
70 |
60 |
$157.54 |
| 83605 |
|
180 |
154 |
$139.38 |
| 96376 |
|
30 |
28 |
$136.64 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
523 |
479 |
$131.72 |
| J7050 |
Infusion, normal saline solution, 250 cc |
342 |
182 |
$114.12 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
115 |
104 |
$102.26 |
| 82077 |
|
65 |
58 |
$97.48 |
| 88304 |
|
14 |
13 |
$68.79 |
| 84145 |
|
12 |
12 |
$61.92 |
| 83735 |
|
59 |
58 |
$60.77 |
| 81003 |
|
164 |
157 |
$59.62 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
112 |
89 |
$53.43 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
76 |
73 |
$37.21 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
14 |
14 |
$35.54 |
| 85610 |
|
58 |
53 |
$35.31 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
25 |
24 |
$29.55 |
| A9270 |
Non-covered item or service |
30 |
26 |
$3.30 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
39 |
39 |
$0.08 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,135 |
907 |
$0.01 |
| 87081 |
|
14 |
14 |
$0.00 |
| 84512 |
|
16 |
16 |
$0.00 |
| 87807 |
|
29 |
27 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
16 |
15 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
17 |
15 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
40 |
32 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
14 |
14 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
35 |
32 |
$0.00 |
| 85027 |
|
29 |
29 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
18 |
16 |
$0.00 |
| 81025 |
|
36 |
36 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
17 |
17 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
14 |
14 |
$0.00 |